Accumulated common variants in the broader fragile X gene family modulate autistic phenotypes

EMBO Molecular Medicine

Volumn 7, Issue 12, 2015, Pages 1565-1579

  Stepniak, Beata ^a   Kästner, Anne ^a,b   Poggi, Giulia ^a   Mitjans, Marina ^a   Begemann, Martin ^a   Hartmann, Annette ^c   Van der Auwera, Sandra ^d   Sananbenesi, Farahnaz ^e   Krueger Burg, Dilja ^a   Matuszko, Gabriela ^e   Brosi, Cornelia ^f   Homuth, Georg ^d   Völzke, Henry ^d   Benseler, Fritz ^a   Bagni, Claudia ^g,h   Fischer, Utz ^f   Dityatev, Alexander ^e   Grabe, Hans Jörgen ^d   Rujescu, Dan ^c   Fischer, Andre ^e,i   Ehrenreich, Hannelore ^a,b   more..

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b Deutsche Forschungsgemeinschaft   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g UNIVERSITY OF LEUVEN   (Belgium)

^h UNIVERSITY OF ROME TOR VERGATA   (Italy)

ⁱ UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

FMR2; FXR1; FXR2; FMR1; MiR 181; PGAS

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 181; UNCLASSIFIED DRUG; FMR1 PROTEIN, HUMAN; FXR1 PROTEIN, HUMAN; FXR2 PROTEIN, HUMAN; MIRN181 MICRORNA, HUMAN; RNA BINDING PROTEIN;

ADULT; AGED; ARTICLE; AUTISM; CONTROLLED STUDY; FEMALE; FRAGILE X GENE; FRAGILE X SYNDROME; GENE; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; SAMPLE SIZE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TRINUCLEOTIDE REPEAT; BIOSYNTHESIS; GENETICS; MUTATION; PATHOPHYSIOLOGY;

AUTISTIC DISORDER; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; MALE; MICRORNAS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA-BINDING PROTEINS; SCHIZOPHRENIA;

EID: 84954369484     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201505696     Document Type: Article

References (73)

1. th edn, text revision, Washington, DC: American Psychiatric Press
2. Ascano M Jr, Mukherjee N, Bandaru P, Miller JB, Nusbaum JD, Corcoran DL, Langlois C, Munschauer M, Dewell S, Hafner M et al (2012) FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature 492: 382-386
3. Ashley CT Jr, Wilkinson KD, Reines D, Warren ST (1993) FMR1 protein: conserved RNP family domains and selective RNA binding. Science 262: 563-566
4. Asquith M, Pasala S, Engelmann F, Haberthur K, Meyer C, Park B, Grant KA, Messaoudi I (2014) Chronic ethanol consumption modulates growth factor release, mucosal cytokine production, and microRNA expression in nonhuman primates. Alcohol Clin Exp Res 38: 980-993
5. Bagni C, Tassone F, Neri G, Hagerman R (2012) Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest 122: 4314-4322
6. Bailey DB Jr, Mesibov GB, Hatton DD, Clark RD, Roberts JE, Mayhew L (1998) Autistic behavior in young boys with fragile X syndrome. J Autism Dev Disord 28: 499-508
7. Bassell GJ, Warren ST (2008) Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 60: 201-214
8. Begemann M, Grube S, Papiol S, Malzahn D, Krampe H, Ribbe K, Friedrichs H, Radyushkin KA, El-Kordi A, Benseler F et al (2010) Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms. Arch Gen Psychiatry 67: 879-888
9. Ceman S, Brown V, Warren ST (1999) Isolation of an FMRP-associated messenger ribonucleoprotein particle and identification of nucleolin and the fragile X-related proteins as components of the complex. Mol Cell Biol 19: 7925-7932
10. Chen EY, Shapleske J, Luque R, McKenna PJ, Hodges JR, Calloway SP, Hymas NF, Dening TR, Berrios GE (1995) The Cambridge Neurological Inventory: a clinical instrument for assessment of soft neurological signs in psychiatric patients. Psychiatry Res 56: 183-204
11. Clifford S, Dissanayake C, Bui QM, Huggins R, Taylor AK, Loesch DZ (2007) Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J Autism Dev Disord 37: 738-747
12. Coffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, Warren ST (2009) Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet 85: 503-514
13. Cornish K, Kogan C, Turk J, Manly T, James N, Mills A, Dalton A (2005) The emerging fragile X premutation phenotype: evidence from the domain of social cognition. Brain Cogn 57: 53-60
14. Cornish KM, Li L, Kogan CS, Jacquemont S, Turk J, Dalton A, Hagerman RJ, Hagerman PJ (2008) Age-dependent cognitive changes in carriers of the fragile X syndrome. Cortex 44: 628-636
15. Crawford DC, Acuna JM, Sherman SL (2001) FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med 3: 359-371
16. Crawford DC, Meadows KL, Newman JL, Taft LF, Scott E, Leslie M, Shubek L, Holmgreen P, Yeargin-Allsopp M, Boyle C et al (2002) Prevalence of the fragile X syndrome in African-Americans. Am J Med Genet 110: 226-233
17. Dahlhaus R, El-Husseini A (2010) Altered neuroligin expression is involved in social deficits in a mouse model of the fragile X syndrome. Behav Brain Res 208: 96-105
18. Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, Stone EF, Chen C, Fak JJ, Chi SW et al (2011) FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146: 247-261
19. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29: 15-21
20. Ehrenreich H, Nave KA (2014) Phenotype-Based Genetic Association Studies (PGAS)-towards understanding the contribution of common genetic variants to schizophrenia subphenotypes. Genes 5: 97-105
21. Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, Marcin C, Montiel-Nava C, Patel V, Paula CS, Wang C et al (2012) Global prevalence of autism and other pervasive developmental disorders. Autism Res 5: 160-179
22. Fernandez E, Li KW, Rajan N, De Rubeis S, Fiers M, Smit AB, Achsel T, Bagni C (2015) FXR2P exerts a positive translational control and is required for the activity-dependent increase of PSD95 expression. J Neurosci 35: 9402-9408
23. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P, Georgieva L, Rees E, Palta P, Ruderfer DM et al (2014) De novo mutations in schizophrenia implicate synaptic networks. Nature 506: 179-184
24. Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, Verkerk AJ, Holden JJ, Fenwick RG Jr, Warren ST et al (1991) Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67: 1047-1058
25. Garber KB, Visootsak J, Warren ST (2008) Fragile X syndrome. Eur J Hum Genet 16: 666-672
26. Garcia-Arocena D, Hagerman PJ (2010) Advances in understanding the molecular basis of FXTAS. Hum Mol Genet 19: R83-R89
27. Gecz J, Gedeon AK, Sutherland GR, Mulley JC (1996) Identification of the gene FMR2, associated with FRAXE mental retardation. Nat Genet 13: 105-108
28. Gecz J, Bielby S, Sutherland GR, Mulley JC (1997) Gene structure and subcellular localization of FMR2, a member of a new family of putative transcription activators. Genomics 44: 201-213
29. Gecz J (2000) The FMR2 gene, FRAXE and non-specific X-linked mental retardation: clinical and molecular aspects. Ann Hum Genet 64: 95-106
30. Geschwind DH (2011) Genetics of autism spectrum disorders. Trends Cogn Sci 15: 409-416
31. Gu Y, Shen Y, Gibbs RA, Nelson DL (1996) Identification of FMR2, a novel gene associated with the FRAXE CCG repeat and CpG island. Nat Genet 13: 109-113
32. Hagerman RJ, Jackson AW III, Levitas A, Rimland B, Braden M (1986) An analysis of autism in fifty males with the fragile X syndrome. Am J Med Genet 23: 359-374
33. Hagerman R, Au J, Hagerman P (2011) FMR1 premutation and full mutation molecular mechanisms related to autism. J Neurodev Disord 3: 211-224
34. Hammer C, Zerche M, Schneider A, Begemann M, Nave KA, Ehrenreich H (2014) Apolipoprotein E4 carrier status plus circulating anti-NMDAR1 autoantibodies: association with schizoaffective disorder. Mol Psychiatry 19: 1054-1056
35. Harris SW, Hessl D, Goodlin-Jones B, Ferranti J, Bacalman S, Barbato I, Tassone F, Hagerman PJ, Herman H, Hagerman RJ (2008) Autism profiles of males with fragile X syndrome. Am J Ment Retard 113: 427-438
36. Hatton DD, Sideris J, Skinner M, Mankowski J, Bailey DB Jr, Roberts J, Mirrett P (2006) Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet A 140A: 1804-1813
37. Heitzer AM, Roth AK, Nawrocki L, Wrenn CC, Valdovinos MG (2013) Brief report: altered social behavior in isolation-reared Fmr1 knockout mice. J Autism Dev Disord 43: 1452-1458
38. Hillman MA, Gecz J (2001) Fragile XE-associated familial mental retardation protein 2 (FMR2) acts as a potent transcription activator. J Hum Genet 46: 251-259
39. Hsu PW, Huang HD, Hsu SD, Lin LZ, Tsou AP, Tseng CP, Stadler PF, Washietl S, Hofacker IL (2006) miRNAMap: genomic maps of microRNA genes and their target genes in mammalian genomes. Nucleic Acids Res 34: D135-D139
40. Hutchison ER, Kawamoto EM, Taub DD, Lal A, Abdelmohsen K, Zhang Y, Wood WH III, Lehrmann E, Camandola S, Becker KG et al (2013) Evidence for miR-181 involvement in neuroinflammatory responses of astrocytes. Glia 61: 1018-1028
41. Jacquemont S, Hagerman RJ, Hagerman PJ, Leehey MA (2007) Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol 6: 45-55
42. Jin P, Zarnescu DC, Ceman S, Nakamoto M, Mowrey J, Jongens TA, Nelson DL, Moses K, Warren ST (2004) Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci 7: 113-117
43. Kästner A, Begemann M, Michel TM, Everts S, Stepniak B, Bach C, Poustka L, Becker J, Banaschewski T, Dose M et al (2015) Autism beyond diagnostic categories: characterization of autistic phenotypes in schizophrenia. BMC Psychiatry 15: 115-127
44. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276
45. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E (2007) The role of site accessibility in microRNA target recognition. Nat Genet 39: 1278-1284
46. King BH, Lord C (2011) Is schizophrenia on the autism spectrum? Brain Res 1380: 34-41
47. Klein J, Vonneilich N, Baumeister SE, Kohlmann T, von dem Knesebeck O (2012) Do social relations explain health inequalities? Evidence from a longitudinal survey in a changing eastern German region. Int J Public Health 57: 619-627
48. Knight SJ, Flannery AV, Hirst MC, Campbell L, Christodoulou Z, Phelps SR, Pointon J, Middleton-Price HR, Barnicoat A, Pembrey ME et al (1993) Trinucleotide repeat amplification and hypermethylation of a CpG island in FRAXE mental retardation. Cell 74: 127-134
49. Kogan CS, Turk J, Hagerman RJ, Cornish KM (2008) Impact of the Fragile X mental retardation 1 (FMR1) gene premutation on neuropsychiatric functioning in adult males without fragile X-associated Tremor/Ataxia syndrome: a controlled study. Am J Med Genet B Neuropsychiatr Genet 147B: 859-872
50. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M et al (2007) A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129: 1401-1414
51. Martin M (2011) Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J 17: 10-12
52. Mondal K, Ramachandran D, Patel VC, Hagen KR, Bose P, Cutler DJ, Zwick ME (2012) Excess variants in AFF2 detected by massively parallel sequencing of males with autism spectrum disorder. Hum Mol Genet 21: 4356-4364
53. Moore CJ, Daly EM, Schmitz N, Tassone F, Tysoe C, Hagerman RJ, Hagerman PJ, Morris RG, Murphy KC, Murphy DG (2004) A neuropsychological investigation of male premutation carriers of fragile X syndrome. Neuropsychologia 42: 1934-1947
54. Mundalil Vasu M, Anitha A, Thanseem I, Suzuki K, Yamada K, Takahashi T, Wakuda T, Iwata K, Tsujii M, Sugiyama T et al (2014) Serum microRNA profiles in children with autism. Molecular autism 5: 40
55. Oberle I, Rousseau F, Heitz D, Kretz C, Devys D, Hanauer A, Boue J, Bertheas MF, Mandel JL (1991) Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 252: 1097-1102
56. Oeth P, del Mistro G, Marnellos G, Shi T, van den Boom D (2009) Qualitative and quantitative genotyping using single base primer extension coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MassARRAY). Methods Mol Biol 578: 307-343
57. Owen MJ, O'Donovan MC, Thapar A, Craddock N (2011) Neurodevelopmental hypothesis of schizophrenia. Br J Psychiatry 198: 173-175
58. Pasciuto E, Bagni C (2014a) SnapShot: FMRP interacting proteins. Cell 159: 218-218
59. Pasciuto E, Bagni C (2014b) SnapShot: FMRP mRNA targets and diseases. Cell 158: 1446-1446
60. Penagarikano O, Mulle JG, Warren ST (2007) The pathophysiology of fragile x syndrome. Annu Rev Genomics Hum Genet 8: 109-129
61. Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, Nelson DL (1991) Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66: 817-822
62. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ et al (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575
63. Rambaldi D, Ciccarelli FD (2009) FancyGene: dynamic visualization of gene structures and protein domain architectures on genomic loci. Bioinformatics 25: 2281-2282
64. Ribbe K, Friedrichs H, Begemann M, Grube S, Papiol S, Kastner A, Gerchen MF, Ackermann V, Tarami A, Treitz A et al (2010) The cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients. BMC Psychiatry 10: 91
65. Santos CB, Costa Lima MA, Pimentel MM (2001) A new PCR assay useful for screening of FRAXE/FMR2 mental impairment among males. Hum Mutat 18: 157-162
66. Schizophrenia Working Group of the PGC (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511: 421-427
67. Stepniak B, Papiol S, Hammer C, Ramin A, Everts S, Hennig L, Begemann M, Ehrenreich H (2014) Accumulated environmental risk determining age at schizophrenia onset: a deep phenotyping-based study. Lancet Psych 1: 444-453
68. Tassone F, Hagerman PJ, Hagerman RJ (2014) Fragile × premutation. J Neurodev Disord 6: 22
69. Tordjman S, Somogyi E, Coulon N, Kermarrec S, Cohen D, Bronsard G, Bonnot O, Weismann-Arcache C, Botbol M, Lauth B et al (2014) Gene x Environment interactions in autism spectrum disorders: role of epigenetic mechanisms. Front Psychiatry 5: 53
70. Van den Oord EJ, Rujescu D, Robles JR, Giegling I, Birrell C, Bukszar J, Murrelle L, Moller HJ, Middleton L, Muglia P (2006) Factor structure and external validity of the PANSS revisited. Schizophr Res 82: 213-223
71. Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang FP et al (1991) Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65: 905-914
72. Völzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, Aumann N, Lau K, Piontek M, Born G et al (2011) Cohort profile: the study of health in Pomerania. Int J Epidemiol 40: 294-307
73. Zhang Y, O'Connor JP, Siomi MC, Srinivasan S, Dutra A, Nussbaum RL, Dreyfuss G (1995) The fragile X mental retardation syndrome protein interacts with novel homologs FXR1 and FXR2. EMBO J 14: 5358-5366